Treatment of symptomatic anemia associated with chronic kidney disease (CKD).

Methoxy polyethylene glycol-epoetin beta (MPG-epoetin beta) or continuous erythropoietin receptor activator (CERA, Mircera) is a long-acting, synthetic erythropoietin protein. In responding to hypoxia, Mircera interacts with erythroid progenitor cells to increase red cell production. The primary advantage of MPG-epoetin beta versus other erythropoiesis-stimulating agents (ESAs) is that it can be dosed less frequently due to its extremely long half-life.

Time to maximum concentration occurs 72 hours after SC administration, and the bioavailability after SC administration is 62%. Elimination half-life:134 ?? 65 hrs after IV administration, 139 ?? 67 hrs after SC administration.

patients with uncontrolled hypertension; patients with a history of hypersensitivity or allergy to the drug

C

Caution

most common: hypertension, diarrhea, nasopharyngitis, headache, and upper respiratory tract infection.

Patients not currently treated with an ESA: 0.6 mcg/kg administered as a single IV or SC injection once every two weeks. Patients currently treated with an ESA: The dose of Mircera should be based on the total weekly ESA dose at the time of conversion.

Be stored at 2-8℃